What LivaNova Holders Bought Into
LivaNova kept beating Wall Street on revenue and earnings through 2025 and 2026, yet its shares often lagged the wider market and even drew “overvalued” labels along the way. For LivaNova shareholders, the return from the start of the year was 48.7%, including dividends. If you had been weighing the China rollout, epilepsy data, and supply bottlenecks back on 1 January 2026, what would have justified taking that risk?
LivaNova has already moved. Pinpoint other ways to investigate the theme among 35 healthcare AI stocks.
The Two LivaNova Stories Investors Were Arguing About
The shares cost US$61.53 at the start of the period, and LivaNova sat between two sharply different stories about what might come next.
Bulls pointed to a Fair Value of US$65, an implied target based on assumptions that revenue could rise 6.4% a year and profit margins might reach 10.7% over three years as aging populations and China expansion lifted device use.
Bears worked off a Fair Value of US$54, using a 5.9% revenue growth assumption while stressing supply bottlenecks and dependence on third party suppliers as key risks to future demand.
What The Results Changed In The LivaNova Debate
Improved manufacturing capacity and a long term supply agreement for oxygenator components addressed the bottleneck concerns that had supported the bearish LivaNova narrative. Revenue rose from US$357.8m to US$393.1m and net income increased from US$26.8m to US$34.3m, lifting net margin from 7.5% to 8.7%. That combination of stronger delivery and still moderate profitability had mixed implications.
The core debate focused on whether supply constraints and reimbursement would ease in practice. For any other medtech stock, it can be useful to track capacity expansions, supply contracts and payer coding decisions against the original growth claims rather than only watching headline guidance.
What LivaNova's Share Price Now Assumes
Today LivaNova changes hands at US$90.2, well above where it started the year. The bearish analyst Narrative on Simply Wall St sees its Fair Value below that level, arguing the stock already embeds confident expectations for margins and cash generation.
For this price to hold up, you would need to believe heavy cardiopulmonary, ERP and digital spending converts cleanly into stronger free cash flow once the current investment cycle eases.
"While management continues to signal a path to 20 to 21% adjusted operating margin in 2026 and 80% free cash flow conversion by 2028, the upward revision of 2026 capital spending guidance and reduction of adjusted free cash flow expectations to US$140 to 160 million show how sensitive those targets are to ongoing cardiopulmonary capacity, ERP and digital health investments, raising the risk that free cash flow and net income fall short of consensus if spending does not taper as quickly as planned."
The price and this Narrative do not agree. → Uncover what this Narrative says LivaNova is actually worth
Another Way Into Healthcare Risk
LivaNova puts you close to devices, but not every healthcare risk sits inside an operating room.
One step away, insurers wrestle with rising medical bills, tighter rules and pressure to justify every dollar spent.
To cope, a large health benefits group is leaning on value based care programs, digital tools and heavier AI use to manage claims, pharmacy costs and complex patients.
The goal is simple, keep coverage attractive while holding margins together as medical trends, specialty drugs and legal pressure all bite.
If you want the same theme from a different angle, that blend of insurance, data and care delivery is where it shows up.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 19% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com